vendredi 16 décembre 2016

Onco Actu du 16 décembre 2016

Onco Actu interrompt sa parution pendant la période des fêtes de fin d'année.
Prochain bulletin : le 2 janvier 2017!


1. Biologie

New insight into cancer-associated liver enzymes could boost drug development [FierceBiotech]

Cancer cells spread way earlier than thought, seeding metastases that cause most deaths [STAT]

2. Etiologie

Herpes Virus Linked to Most Common Type of Childhood Cancer [ASH]

2.7 Etiologie - Obésité

New obesity figures for England show growing problem [Cancer Research UK]

3. Prévention

Smoking and drinking among young people at lowest level on record [The Guardian]

3.1 Tabac

FDA takes action on applications seeking to market modified risk tobacco products [FDA]

FDA denies Swedish Match request to remove warnings [Reuters]

3.6 Prévention - Activité physique

Pokémon no-go: game's exercise effects short-lived in most players [NHS Choices]

4.12 Biopsies liquides

One Patient, Two Cancer DNA Tests, Two Different Results [The Atlantic]


Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells [Astellas]

4.2 Dép., diag. & prono. - Génome

Genos Will Sequence Your Genes—And Help You Sell Them to Science [Wired]


4.5 Dép., diag. & prono. - Colorectal

Many Early Onset Colon Cancers are Caused by Genetic Mutations Passed Through Families [OSU]

5. Traitements

Novocure's noninvasive brain cancer therapy could succeed in ovarian cancer [FierceBiotech]

A new type of molecular medicine may be needed to halt cancers [The Economist]

5.10 Traitements - Essais

Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer [Pfizer]

Xtandi fails a combo study, blocking a path to continued use for Pfizer, Astellas [EndPoints]

Pfizer's Xtandi fails in progression trial vs. J&J's Zytiga [Reuters]

5.12.2 Immunothérapies - CAR-T

Opinion: Balancing Risks and Rewards of CAR T-Cell Therapy [The Scientist]

Father of patient in Juno immunotherapy trial speaks out: ‘He died for greed’ [STAT]

5.2 Pharma

Nanobiotix reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial [Nanobiotix]

5.2.1 Pharma - Partenariats

Cancer Research UK and Bicycle Therapeutics have collaborated to trial new therapy for advanced solid tumours [Cancer Research UK]

5.2.3 Pharma - économie

GSK chief: Immuno-oncology isn't cost-effective for global cancer treatment [FiercePharma]

R&D productivity recovery? Deloitte sees no sign just yet [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

NICE and the FDA working together [NICE]

New drug OKs fell off a cliff in 2016 and the FDA wants you to know why [EndPoints]

CDER New Drug Review: 2016 Update [FDA]

5.5 ASCO

Monica M. Bertagnolli, MD, Elected ASCO President for 2018-2019 Term [ASCO]

6. Lutte contre les cancers

Breast cancer gene testing in the US rose after Angelina Jolie announcement [Cancer Research UK]

'Angelina Jolie effect' boosted genetic testing rates, study suggests [The Guardian]

6.10.1 Politiques (USA)

A Closer Look at the 21st Century Cures Act [Cancer Research Catalyst]

Drain Bethesda’s Swamp: Replace Francis Collins as NIH Director [it is NOT junk]

6.6 Publications

High-profile Science paper retracted for misconduct [Retraction Watch]

Prominent cancer researcher committed nearly 30 acts of misconduct [Retraction Watch]

6.7 DMP, Big Data & applis

Should Big Data Pick Your Next Doctor? [Forbes]

6.7.1 Bioinformatique

Research transparency depends on sharing computational tools, says John Ioannidis [Stanford Medicine]